Press Releases
-
May 31, 2011
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jeffrey Cooper, Chief Financial Officer of BioMarin, will present a company update at the Jefferies Global Healthcare Conference in...
-
May 18, 2011
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the UBS Global Specialty...
-
May 3, 2011
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Bank of America Merrill Lynch...
-
Apr 28, 2011Net Product Revenue Growth of 30% in the First Quarter of 2011; Improved Top and Bottom-Line Guidance
Financial Highlights ($ in millions, except per share data, unaudited) Item Q1 2011 Q1 2010 Comparison Total BioMarin Revenue $109.5 28.8% increase Total Net Product Revenue $109.1 29.7% increase...
-
Apr 26, 2011
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Steve Aselage, Chief Business Officer of BioMarin, will present a company update at the Deutsche Bank Healthcare Conference in...
-
Mar 28, 2011
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, April 28, at 5:00...
-
Mar 18, 2011Additional posters at ACMG describe ongoing studies designed to further examine the use of KUVAN® for PKU, with endpoints of neuropsychiatric effects and long-term safety in children
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today preliminary results from ADAPT (A Diversified Approach for PKU Treatment) in an abstract (Abstract #91, Mental Health Screening in...
-
Mar 8, 2011
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Barclays Global Healthcare...
-
Mar 1, 2011
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Dan Maher, Senior Vice President of Product Development of BioMarin, will present a company update at the Cowen Health Care...
-
Feb 22, 2011
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Joshua Grass, Vice President of Corporate and Business Development of BioMarin, will present a company update at the Citi Global...
-
Feb 17, 2011Net Product Revenue Growth of 17% in 2010; Late Stage Clinical Pipeline Advancing
Financial Highlights ($ in millions, except per share data, unaudited) Item FY 2010 FY 2009 Comparison Total BioMarin Revenue $376.3 15.9% increase Total Net Product Revenue $369.7 17.1% increase...
-
Feb 1, 2011
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that it has initiated a pivotal Phase 3 trial for N-acetylgalactosamine 6-sulfatase (GALNS or BMN 110), intended for the treatment of...
-
Jan 24, 2011Conference Call and Webcast on Thursday, February 17 at 5:00 p.m. ET
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, February 17, at...
-
Jan 19, 2011
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that it has initiated a Phase 1/2 trial for BMN 701, a novel fusion protein of insulin-like growth factor 2 and acid alpha glucosidase...
-
Jan 11, 2011
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced the initiation of a Phase 1/2 trial for BMN 673, a poly ADP-ribose polymerase (PARP) inhibitor in development for the treatment of...
-
Jan 5, 2011
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the J.P. Morgan 29th Annual Healthcare...
-
Dec 14, 2010
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK has completed review of the Clinical Trial Application...
-
Dec 7, 2010
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Joshua Grass, Vice President of Corporate and Business Development of BioMarin, will present a company update at the Deutsche Bank...
-
Dec 2, 2010
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that the Medicines and Healthcare Products Regulatory Agency (MHRA) in the UK has completed review of the Clinical Trial Application...
-
Nov 29, 2010
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jeffrey Cooper, Chief Financial Officer of BioMarin, will present a company update at the Piper Jaffray Healthcare Conference in...
-
Nov 9, 2010
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today that six holders of its 2.50% Convertible Senior Subordinated Notes due 2013 have agreed to exchange $87.0 million in aggregate...
-
Oct 28, 2010Strong Performance in Commercial Business; Best Quarter Ever for Net Product Revenue
Financial Highlights ($ in millions, except per share data, unaudited) Item Q3 2010 Q3 2009 Comparison Total BioMarin Revenue $97.8 21.0% increase Total Net Product Revenue $96.6 23.2% increase...
-
Oct 19, 2010
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced its program for BMN-111, a peptide therapeutic for the treatment of achondroplasia. BioMarin plans to file an IND in the fourth quarter...
-
Oct 14, 2010
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) will host a Research and Development Day for the investment community on Tuesday, October 19, 2010 from 8:00 a.m. to 12:00 p.m. at the St. Regis Hotel...
-
Oct 7, 2010
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, October 28, at...
-
Oct 5, 2010
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) will host a Research and Development Day for the investment community on Tuesday, October 19, 2010 from 8:00 a.m. to 12:00 p.m. at the St. Regis Hotel...
-
Sep 23, 2010
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced today the appointment of William D. Young and Kenneth M. Bate to its Board of Directors. "We are extremely pleased to welcome William Young...
-
Sep 14, 2010
BioMarin Pharmaceutical Inc. today announced that Joshua Grass, Vice President, Corporate and Business Development of BioMarin, will present a company update at the UBS Global Life Sciences...
-
Sep 9, 2010
BioMarin Pharmaceutical Inc. today announced that Dan Maher, Senior Vice President of Product Development of BioMarin, will present a company update at the Stifel Nicolaus Healthcare Conference in...
-
Sep 8, 2010
BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Robert W. Baird Healthcare Conference in New York...
-
Sep 7, 2010
BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Morgan Stanley Global Healthcare Conference in...
-
Sep 1, 2010Kuvan Patients Show Improvements in Neurocognitive Functioning, Mood and Behavior
BioMarin Pharmaceutical Inc. announced today that results from investigator-sponsored studies on Kuvan (sapropterin dihydrochloride) are being presented at the 2010 Annual Symposium of the Society...
-
Aug 30, 2010
BioMarin Pharmaceutical Inc. announced today that it has received orphan drug designation from the U.S. Food and Drug Administration (FDA) for BMN-701, a novel fusion of insulin-like growth factor...
-
Aug 17, 2010High Affinity ZC-701 Fusion Enzyme Replacement Therapy Demonstrates Superior Potency and Efficacy to Myozyme in Nonclinical Studies Phase I/II Clinical Study In Late Onset Pompe Expected to Start in Q1 2011 Conference Call and Webcast to Be Held Today at 5:00 p.m. ET
BioMarin Pharmaceutical Inc. announced today that it has acquired ZyStor Therapeutics, Inc. (ZyStor), a privately-held biotechnology company developing enzyme replacement therapies (ERT) for the...
-
Aug 17, 2010
BioMarin Pharmaceutical Inc. announced today that the first subject has initiated treatment in a Phase 3b study (PKU-016) to evaluate the effects of Kuvan (sapropterin dihydrochloride) on...
-
Aug 2, 2010R&D Pipeline Advancing Rapidly; Core Products Revenue In-Line Despite Challenging Economic Climate Firdapse Launch Delay Contributes to Reduction in Guidance Conference Call and Webcast to Be Held Today at 5:00 p.m. ET
Financial Highlights ($ in millions, except per share data, unaudited) Item Q2 2010 Q2 2009 Comparison Total BioMarin Revenue $92.0 11.1% increase Total Net Product Revenue $90.6 11.2% increase...
-
Aug 2, 2010Conference Call and Webcast to Be Held Today at 5:00 p.m. ET
BioMarin Pharmaceutical Inc. announced today an update in the Phase 2 clinical study of PEG-PAL (PEGylated recombinant phenylalanine ammonia lyase) for the treatment of phenylketonuria (PKU). Data...
-
Aug 2, 2010BMN 195 Program Discontinued due to Pharmaceutical and Pharmacokinetic Challenges
BioMarin Pharmaceutical Inc. announced today that it has completed the Phase 1 clinical study of BMN 195, a small molecule utrophin up-regulator, for the treatment of Duchenne muscular dystrophy...
-
Jul 6, 2010
BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Monday, August 2, at 5:00 p.m. ET to...
-
Jun 17, 2010
BioMarin Pharmaceutical Inc. today announced that Jeffrey Cooper, Chief Financial Officer of BioMarin, will present a company update at the Wells Fargo Healthcare Conference in Boston on Thursday,...
-
Jun 10, 2010
BioMarin Pharmaceutical Inc. today announced that Jeffrey Cooper, Chief Financial Officer of BioMarin, will present a company update at the Goldman Sachs 31st Annual Healthcare Conference in Los...
-
Jun 8, 2010
BioMarin Pharmaceutical Inc. today announced that Steve Aselage, Executive Vice President and Chief Business Officer of BioMarin, will present a company update at the William Blair 30th Annual...
-
May 19, 2010
BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will present a company update at the Citi Global Healthcare Conference in New York...
-
May 12, 2010
BioMarin Pharmaceutical Inc. today announced that Jeffrey Cooper, Chief Financial Officer of BioMarin, will present a company update at the Baird Growth Stock Conference in Chicago on Wednesday,...
-
May 4, 2010
BioMarin Pharmaceutical Inc. today announced that Dan Maher, Senior Vice President of Product Development of BioMarin, will present a company update at the JMP Securities Research Conference in...
-
Apr 29, 2010First Quarter Profitability Driven by Continued Growth of Naglazyme Conference Call and Webcast to Be Held Today at 5:00 p.m. ET
Financial Highlights ($ in millions, except per share data, unaudited) Item Q1 2010 Q1 2009 Comparison Total BioMarin Revenue $85.0 14.8% increase Total Net Product Revenue $84.1 16.9% increase...
-
Apr 29, 2010GALNS Demonstrates Benefits in Endurance and Pulmonary Function Endpoints Phase III Trial Expected to Start by Q4 2010 Conference Call and Webcast to Be Held Today at 5:00 p.m. ET
BioMarin Pharmaceutical Inc. today announced positive results for the Phase I/II trial for BMN 110 or N-acetylgalactosamine 6-sulfatase (GALNS), intended for the treatment of the lysosomal storage...
-
Apr 28, 2010
BioMarin Pharmaceutical Inc. today announced that Steve Aselage, Executive Vice President and Chief Business Officer of BioMarin, will present a company update at the Deutsche Bank 35th Annual...
-
Apr 19, 2010
BioMarin Pharmaceutical Inc. announced today that Firdapse(TM) (3,4-diaminopyridine) is now commercially available in the European Union (E.U.) for the treatment of the rare autoimmune disease...
-
Apr 1, 2010
BioMarin Pharmaceutical Inc. today announced that Jean-Jacques Bienaime, Chief Executive Officer of BioMarin, will host a conference call and webcast on Thursday, April 29, at 5:00 p.m. ET to...